The next focusIR Investor Webinar takes place tomorrow with guest speakers from WS Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksPoolbeg Pharma Share News (POLB)

Share Price Information for Poolbeg Pharma (POLB)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 13.55
Bid: 13.40
Ask: 13.70
Change: -0.20 (-1.45%)
Spread: 0.30 (2.239%)
Open: 13.75
High: 13.80
Low: 13.40
Prev. Close: 13.75
POLB Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

TRADING UPDATES: Diversified Energy offers dividend alternative

Thu, 15th Feb 2024 16:02

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News:

----------

Forward Partners Group PLC - London-based early-stage technology-focused investor - Announces that the 'change of control' conditions relating to the takeover of the company by Molten Ventures have been satisfied. Explains the scheme by which the takeover will be facilitated is now subject to court approval at a hearing on March 12. Subject to this approval, the scheme is expected to become effective on March 14.

----------

Tekcapital PLC - London-based intellectual property investor - Provides an update on Guident Ltd's strategic partnership with AuVe Tech OU. Guident is a Tekcapital portfolio company. Guident plans to integrate its autonomous vehicle remote monitoring, control, assistance, and passenger support services with the autonomous shuttle, MiCa from Auve Tech. Notes Auve Tech is an Estonia-based company that specializes in the development and manufacturing of autonomous transportation systems.

----------

Sovereign Metals Ltd - Malawi-focused mining exploration and development company - Appoints Marco Da Cunha, as its new lead environmental, social and governance officer. Notes Da Cunha has almost 20 years of experience in the field of environmental and social management.

----------

Tower Resources PLC - Africa-focused oil and gas company - Reaches agreement for the repayment of the outstanding balance owed to Energy Exploration Capital Partners, LLC in accordance with the terms announced on January 16, 2023. Further, announces subscription for around 3.33 billion shares at 0.018 pence each. Explains this will raise GBP600,000 which will fund working capital, including the repayment to EECP. Funds will also help progress work on the company's licenses; including the Thali PSC, offshore Cameroon, PEL 96 in Namibia, and the Algoa-Gamtoos license in South Africa. Tower Resources says the subscription will be issued in two tranches with a first tranche of 1.05 billion shares and a second tranche of 2.29 billion shares.

----------

Power Metal Resources PLC - exploration company focused on North America, Africa, and Australia - Issues update concerning its uranium property portfolio focused on the Athabasca Basin area in Saskatchewan, Canada. Says the newly acquired Richards Lake Uranium Property was staked during the most recent mineral administration registry Saskatchewan electronic registry system claim. Power Metals points out the Richards Lake acquisition takes the company's uranium portfolio to eighteen properties.

----------

Poolbeg Pharma PLC - London-based clinical-stage biopharmaceutical company targeting diseases with a high unmet medical need - Says Cathal Friel, co-founder, substantial shareholder, and currently non-executive chair, will become executive chair effective immediately. Friel says: "I believe Poolbeg is well positioned for success. As part of my ongoing commitment to the company, I also intend to start increasing my shareholding in Poolbeg as and when I am able to do so". Further, company launches employee incentive performance plan. Friel says this will "incentivise and retain key members of the Poolbeg management team."

----------

Diversified Energy Company PLC - Alabama, US-based oil and gas production company - Intends to offer shareholders two options with regard to payment of the dividend announced in November. Shareholders can either receive the dividend on March 28 as normal. Or, they can waive some or all of the payout in order to have their shares purchased in a tender offer for cash. Explains the tender price will include a premium. Diversified Energy believes that the current share price does not reflect the quality of the assets nor the significant opportunities for its long-term strategy. Therefore, considers the repurchase of shares a prudent use of capital and in the best interests of the shareholders. Plans to fund the tender offer from existing resources.

----------

By Jeremy Cutler, Alliance News reporter

Comments and questions to newsroom@alliancenews.com

Copyright 2024 Alliance News Ltd. All Rights Reserved.

More News
21 Dec 2022 19:20

TRADING UPDATES: Atlantis Japan underperforms; Bellevue lowers payout

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Wednesday and not separately reported by Alliance News:

Read more
21 Dec 2022 13:37

Poolbeg identifies new drug candidates with OneThree

(Sharecast News) - Biopharmaceutical company Poolbeg Pharma has successfully identified potential new drug candidates from its respiratory syncytial virus (RSV) artificial intelligence (AI) programme with OneThree Biotech, it announced on Wednesday.

Read more
14 Dec 2022 21:54

TRADING UPDATES: Poolbeg acquires license; Afentra expects PSA delay

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Wednesday and not separately reported by Alliance News:

Read more
14 Dec 2022 16:14

Poolbeg secures exclusive licence to possible obesity drug tech

(Sharecast News) - Infectious disease-focussed biopharmaceutical company Poolbeg Pharma has acquired an exclusive licence from AnaBio sister company InsuCaps, it announced on Wednesday, to use its patented microencapsulation and nanoencapsulation oral delivery technologies in metabolic syndrome-related diseases, including obesity, pre-diabetes and diabetes.

Read more
2 Dec 2022 19:33

TRADING UPDATES: Time Out eyes Riyadh; MTI Wireless wins deal

(Alliance News) - The following is a round-up of updates by London-listed companies, issued this week and not separately reported by Alliance News:

Read more
15 Nov 2022 17:25

Poolbeg Pharma wins funding for oral vaccine development

(Alliance News) - Poolbeg Pharma PLC on Tuesday said it has received funding from the Irish Government to improve the manufacturing, distribution and administration of its oral vaccines.

Read more
8 Nov 2022 13:06

Poolbeg announces 'breakthrough' in AI drug target programme

(Sharecast News) - Infectious disease pharmaceutical developer Poolbeg Pharma announced a "significant breakthrough" in its artificial intelligence (AI) programme with partner OneThree Biotech on Tuesday, through the discovery of novel drug targets for the treatment of respiratory syncytial virus (RSV).

Read more
8 Nov 2022 12:18

IN BRIEF: Poolbeg makes "significant breakthrough" in AI programme

Poolbeg Pharma PLC - London-based clinical stage infectious disease pharmaceutical company - Announces "significant breakthrough" in its artificial intelligence programme with its partner OneThree Biotech Inc, a New York-based drug discovery-focused firm. Says breakthrough is the discovery of novel drug targets for the treatment of respiratory syncytial virus. The identification of these targets allow for the final stages of the programme to start, Poolbeg explains. This will involve the identification of small molecule inhibitors to treat RSV infections. The team is "particularly excited", the firm says, as these include a range of targets for which there are known drugs with existing Phase I safety and tolerability data. Results are expected before the end of 2022.

Read more
4 Oct 2022 14:14

Poolbeg Pharma upbeat on US patent application progress

(Sharecast News) - Infectious disease pharmaceutical company Poolbeg Pharma updated the market on its intellectual property (IP) position around 'POLB 001' on Tuesday, which it described as a small molecule immunomodulator for the treatment of severe influenza.

Read more
4 Oct 2022 10:14

Poolbeg expects formal patent grant soon to treat hypercytokinemia

(Alliance News) - Poolbeg Pharma PLC on Tuesday said that the US Patent & Trademarks Office has indicated that its patent application concerning the use of POLB 001 and its homologues for the treatment of hypercytokinemia is allowable.

Read more
4 Oct 2022 08:46

LONDON MARKET OPEN: Stocks rise as market sentiment recovers

(Alliance News) - Stock prices in London opened sharply higher on Tuesday, lifted by more positive market sentiment following the UK government's tax U-turn, as well as some positive trading updates.

Read more
4 Oct 2022 07:52

LONDON BRIEFING: Pound, oil, gold up; Truss vows fiscal responsibility

(Alliance News) - Stocks in London are called higher on Tuesday, as the market watches closely for further clues regarding the UK's economic direction.

Read more
27 Sep 2022 06:59

IN BRIEF: Poolbeg Pharma teams up for Melioidosis vaccine

Poolbeg Pharma PLC - London-based pharmaceutical company - On Wednesday reported it a signed an in-license agreement for the development of a Melioidosis vaccine candidate with University College Dublin. Melioidosis is an infectious disease spread by a bacterium in contaminated soil or water. It has a minimum fatality rate of around 10% and no vaccine for the disease exists. Poolbeg's late preclinical stage vaccine candidate has the name POLB 003. It is being developed following several years of research.

Read more
21 Sep 2022 16:18

Poolbeg inks exclusive deal for melioidosis vaccine candidate

(Sharecast News) - Clinical-stage infectious disease pharmaceutical company Poolbeg Pharma has signed an exclusive licence agreement with University College Dublin (UCD), it announced on Wednesday, for a late preclinical-stage vaccine candidate for melioidosis.

Read more
6 Sep 2022 14:04

IN BRIEF: Poolbeg shares rises on narrowed loss, strong pipeline

Poolbeg Pharma PLC - London-based pharmaceutical company - In the six months ended June 30, narrows its pretax loss to GBP1.7 million from GBP2.3 million loss the year prior. Does not post a revenue figure, unchanged from the previous year. Research & development expenses rise to GBP657,000 from GBP414,000. Notes "significant" progress on POLB 001, its treatment for severe influenza. Expects outputs from its respiratory syncytial virus and influenza artificial intelligence programmes by the end of 2022 and the second quarter of 2023, respectively. Adds it has "strong financial resources available to progress its products and platforms."

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.